Drug Targets In Kinetoplastid Parasites (advances In Experimental Medicine And Biology)

"If viewed globally, the parasitic diseases pose an increasing threat to human health and welfare. The diseases caused by kinetoplastid protozoan parasites like Leishmania and Trypanosoma continue as a cause of suffering for many millions of people in both tropical and subtropical regions of the world. Leishmania species are found throughout Latin America, Africa and Asia. Trypanosoma cruzi that cause Chagas' disease is endemic in Latin America, while members of Trypanosoma brucei group are found in sub-Saharan Africa. Although the past two decades has witnessed commendable research efforts and technical advances in our understanding of the biochemistry, molecular and cell biology of these pathogens, the dreaded protozoal diseases caused by these organisms threaten mankind. Therapeutic tools for the treatment of most parasitic diseases are extremely limited. The development of parasites resistant to many of the available drugs is also responsible for the depressing picture of disease persistence and death. Development of commercially available vaccines is still far from reality, though research and trial programs continue."--Publisher's description Arsenite resistance in leishmania and possible drug targets / Gaganmeet Singh, K.G. Jayanarayan, Chinmoy S. Dey Unique characteristics of the kinetoplast DNA replication machinery provide potential drug targets in trypanosomatids / Dotan Sela ... [et al.] Drugs and transporters in kinetoplastid protozoa / Scott M. Landfear Selective lead compounds against kinetoplastid tubulin / R.E. Morgan and K.A. Werbovetz Fishing for anti-leishmania drugs: principles and problems / Emanuela Handman ... [et al.] Sterol 14-demethylase inhibitors for trypanosoma cruzi infections / Frederick S. Buckner Histone deacetylases / David Horn Targeting glycoproteins or glycolipids and their metabolic pathways for antiparasite therapy / Sumi Mukhopadhyay nee Bandyopadhyay and Chitra Mandal DNA topoisomerases of leishmania: the potential targets for anti-leishmanial therapy / Benu Brata Das, Agneyo Ganguly and Hemanta K. Majumder Antiparasitic chemotherapy: tinkering with the purine salvage pathway / Alok Kumar Datta, Rupak Datta and Banibrata Sen Searching the tritryp genomes for drug targets / Peter J. Myler Purine and pyrimidine metabolism in leishmania / Nicola S. Carter ... [et al.]. Front Matter....Pages i-xix Arsenite Resistance in Leishmania and Possible Drug Targets....Pages 1-8 Unique Characteristics of the Kinetoplast DNA Replication Machinery Provide Potential Drug Targets in Trypanosomatids....Pages 9-21 Drugs and Transporters in Kinetoplastid Protozoa....Pages 22-32 Selective Lead Compounds against Kinetoplastid Tubulin....Pages 33-47 Fishing for Anti-Leishmania Drugs: Principles and Problems....Pages 48-60 Sterol 14-Demethylase Inhibitors for Trypanosoma cruzi Infections....Pages 61-80 Histone Deacetylases....Pages 81-86 Targeting Glycoproteins or Glycolipids and Their Metabolic Pathways for Antiparasite Therapy....Pages 87-102 DNA Topoisomerases of Leishmania : The Potential Targets for Anti-Leishmanial Therapy....Pages 103-115 Antiparasitic Chemotherapy:....Pages 116-132 Searching the Tritryp Genomes for Drug Targets....Pages 133-140 Purine and Pyrimidine Metabolism in Leishmania ....Pages 141-154 Back Matter....Pages 155-157 If viewed globally, the parasitic diseases pose an increasing threat to human health and welfare. The diseases caused by kinetoplastid protozoan parasites like Leishmania and Trypanosoma continue as a cause of suffering for many millions of people in both tropical and subtropical regions of the world. Leishmania species are found throughout Latin America, Africa and Asia. Trypanosoma cruzi that cause Chagasa (TM) disease is endemic in Latin America, while members of Trypanosoma brucei group are found in sub-Saharan Africa. Although the past two decades has witnessed commendable research effort The dreaded protozoal diseases caused by a number of Kinetoplastid parasites threaten mankind, as therapeutic tools for the treatment of most parasitic diseases are extremely limited.